Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII

Epidermal growth factor receptor (EGFR) is frequently amplified and/or mutated in a number of human tumours and abnormal signalling from this receptor is believed to contribute to the malignant phenotype seen in these tumours. Gefitinib is a small molecule inhibitor that specifically binds and inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Pedersen, M W, Pedersen, N, Ottesen, L H, Poulsen, H S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361662/
https://www.ncbi.nlm.nih.gov/pubmed/16189524
http://dx.doi.org/10.1038/sj.bjc.6602793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361662/
https://www.ncbi.nlm.nih.gov/pubmed/16189524
http://dx.doi.org/10.1038/sj.bjc.6602793

Ejemplares similares